Fusion variants of the ALK gene — the key to modern therapy for patients with ALK-positive non-small-cell lung cancer

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients2017 · 224 citations
2. 2Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study2019 · 498 citations
3. 3Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK -Positive Non–Small-Cell Lung Cancer2016 · 262 citations
4. 4EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK + non‐small cell lung cancer2018 · 139 citations
5. 5Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase ( ALK )‐rearranged non‐small cell lung cancer2019 · 32 citations